Zentalis Pharmaceuticals, Inc. Common Stock
Symbol: ZNTL (NASDAQ)
1.48
▼ (-7.81%) -0.125
Company Description:
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Key Stats
- Today's Open: $1.6
- Today's High: $1.63
- Today's Low: $1.465
- Today's Volume: 818.15K
- Yesterday Close: $1.6
- Yesterday High: $1.65
- Yesterday Low: $1.59
- Yesterday Volume: 388.41K
- Last Min Volume: 6
- Last Min High: $1.475
- Last Min Low: $1.475
- Last Min VWAP: $1.475
Company Profile
- Name: Zentalis Pharmaceuticals, Inc. Common Stock
- Website: https://www.zentalis.com
- Listed Date: 2020-04-03
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001725160
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $117.58M
- Round Lot: 100
- Outstanding Shares: 72.14M
- Asset Type: CS
RECENT FILINGS FOR ZNTL
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-26 | 8-K | View |
| 2025-08-06 | 10-Q | View |
| 2025-08-06 | 8-K | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 4 | View |
| 2025-06-18 | 8-K | View |
| 2025-06-02 | 8-K | View |
| 2025-05-23 | DEFA14A | View |
| 2025-05-20 | 8-K | View |
| 2025-05-14 | S-8 | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
| 2025-05-14 | SCHEDULE 13G/A | View |
| 2025-05-13 | SCHEDULE 13G/A | View |
| 2025-04-30 | 4 | View |
| 2025-04-30 | DEFA14A | View |
Latest News on ZNTL